Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16553105 | 0.93 | LMNA (0.54) | LMNACYP3A4ALOX15PTPN1STAT3 | |
| SCHEMBL3504963 | 0.92 | LMNA (0.48) | LMNACYP3A4ALOX15PTPN1STAT3 | |
| SCHEMBL21779588 | 0.90 | LMNA (0.46) | LMNACYP3A4ALOX15PTPN1STAT3 | |
| SCHEMBL129843 | 0.89 | LMNA (0.53) | LMNACYP3A4ALOX15PTPN1STAT3 | |
| SCHEMBL180439 | 0.88 | LMNA (0.49) | LMNACYP3A4ALOX15PTPN1STAT3 | |
| SCHEMBL21779540 | 0.84 | LMNA (0.51) | LMNACYP3A4ALOX15PTPN1STAT3 | |
| SCHEMBL21779554 | 0.83 | LMNA (0.47) | LMNACYP3A4ALOX15PTPN1STAT3 | |
| SCHEMBL3503692 | 0.82 | LMNA (0.49) | LMNACYP3A4ALOX15PTPN1STAT3 | |
| SCHEMBL25380939 | 0.82 | LMNA (0.59) | LMNACYP3A4ALOX15PTPN1STAT3 | |
| SCHEMBL27843244 | 0.81 | LMNA (0.52) | LMNACYP3A4ALOX15PTPN1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240306688-A1 | METHOD OF MITIGATING OFF-ODORS | GIVAUDAN SA (CH) | 2024-09-19 | — | — | US | claimed |
| EP-4391827-A1 | METHOD OF MITIGATING OFF-ODORS | Givaudan SA (CH) | 2024-07-03 | — | — | EP | claimed |
| EP-4356894-A1 | SUSTAINABLE PRODUCT WITH MALODORS | Beiersdorf AG (DE) | 2024-04-24 | — | — | EP | claimed |
| WO-2023025549-A1 | METHOD OF MITIGATING OFF-ODORS | GIVAUDAN SA (CH) | 2023-03-02 | — | — | WO | claimed |
| US-20250302014-A1 | WASP PEST MANAGEMENT SYSTEM | TONER DARADH (IE) | 2025-10-02 | — | — | US | disclosed |
| EP-4518647-A1 | WASP PEST MANAGEMENT SYSTEM | Toner, Daradh (IE) | 2025-03-12 | — | — | EP | disclosed |
| EP-3335140-B1 | SYSTEMS, APPARATUS, AND METHODS FOR ANALYZING AND PREDICTING CELLULAR PATHWAYS | MASSACHUSETTS INST TECHNOLOGY (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20240306688-A1 | METHOD OF MITIGATING OFF-ODORS | GIVAUDAN SA (CH) | 2024-09-19 | — | — | US | disclosed |
| US-20240277012-A1 | DUPLICATE BEVERAGE | WANG JIE (US) | 2024-08-22 | — | — | US | disclosed |
| EP-4391827-A1 | METHOD OF MITIGATING OFF-ODORS | Givaudan SA (CH) | 2024-07-03 | — | — | EP | disclosed |
| EP-4356894-A1 | SUSTAINABLE PRODUCT WITH MALODORS | Beiersdorf AG (DE) | 2024-04-24 | — | — | EP | disclosed |
| CN-117897223-A | Plant protein-based microcapsules | 弗门尼舍有限公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2013083588-A1 | MICROBICIDAL COMPOSITION | UNILEVER N.V. (NL) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013083578-A2 | MICROBICIDAL COMPOSITION | UNILEVER N.V. (NL) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013083579-A2 | MICROBICIDAL COMPOSITION | UNILEVER N.V. (NL) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013083586-A2 | MICROBICIDAL COMPOSITION | UNILEVER N.V. (NL) | 2013-06-13 | — | — | WO | disclosed |
| US-20130039962-A1 | ENCAPSULATES | ENCAPSYS, LLC | 2013-02-14 | — | — | US | disclosed |
| WO-2013022949-A1 | ENCAPSULATES | THE PROCTER & GAMBLE COMPANY (US) | 2013-02-14 | — | — | WO | disclosed |
| EP-2468239-A1 | Encapsulates | Procter & Gamble International Operations SA (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-20100248390-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING LIGANDS OF ODORANT RECEPTORS | DUKE UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039962-A1 | ENCAPSULATES | ABCB4, PPIB, FLNB | LMNA 2056/4885CYP3A4 746/4885ALOX15 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.